SHATTUCK LABS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.75 USD | -3.85% |
|
+2.58% | +50.77% |
| May. 02 | Shattuck Labs, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Mar. 04 | Shattuck Labs, Inc. Announces Board Appointments | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 2.1M | Sales 2025 * | 1.32M | Capitalization | 511M |
|---|---|---|---|---|---|
| Net income 2024 * | -82M | Net income 2025 * | -97M | EV / Sales 2024 * | 244 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 386 x |
| P/E ratio 2024 * |
-6.87
x | P/E ratio 2025 * |
-6.52
x | Employees | 75 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.67% |
More Fundamentals
* Assessed data
More news
Latest transcript on Shattuck Labs, Inc.
More recommendations
More press releases
| 1 day | -3.85% | ||
| 1 week | +2.58% | ||
| Current month | +2.58% | ||
| 1 month | +15.47% | ||
| 3 months | +12.33% | ||
| 6 months | +388.64% | ||
| Current year | +50.77% |
1 week
10.61
11.62
1 month
8.7111.62
Current year
6.9811.62
1 year
1.3311.62
3 years
1.3331.23
5 years
1.3360.52
10 years
1.3360.52
| Managers | Title | Age | Since |
|---|---|---|---|
Taylor Schreiber
FOU | Founder | 44 | 15-12-31 |
Andrew Neill
DFI | Director of Finance/CFO | 38 | 19-06-30 |
Stephen Stout
CMP | Compliance Officer | 49 | 20-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Neil Gibson
BRD | Director/Board Member | 67 | 16-10-31 |
| Chairman | 67 | 17-12-31 | |
Michael Lee
BRD | Director/Board Member | 45 | 20-05-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-07 | 10.75 | -3.85% | 265,278 |
| 24-05-06 | 11.18 | +3.71% | 309,767 |
| 24-05-03 | 10.78 | -2.88% | 255,663 |
| 24-05-02 | 11.1 | +2.21% | 250,934 |
| 24-05-01 | 10.86 | +3.63% | 202,349 |
Delayed Quote Nasdaq, May 07, 2024 at 04:00 pm EDT
More quotes
Shattuck Labs, Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Its lead product candidate, SL-172154, is designed to simultaneously inhibit the CD47/SIRPa macrophage checkpoint interaction and activate the CD40 costimulatory receptor to induce an antitumor immune response. It is conducting a Phase IA/B clinical trial in patients with acute myeloid leukemia (AML) and HR-MDS. It has completed the Phase IA dose-escalation portion of this clinical trial and are enrolling patients in the Phase IB expansion cohorts evaluating SL-172154 in combination with azacitidine in frontline HR-MDS or frontline TP53 mutant (TP53m) AML. It has developed the ARC platform to address the need for a single therapeutic that consolidates multiple immune functions.
Calendar
2024-06-07
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
10.75
USD
Average target price
15.75
USD
Spread / Average Target
+46.51%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +50.77% | 511M | |
| +21.74% | 46.4B | |
| -0.97% | 41.75B | |
| +47.07% | 41.37B | |
| -3.52% | 29.71B | |
| +11.12% | 26.01B | |
| -19.37% | 19.52B | |
| +31.18% | 12.43B | |
| -0.04% | 12.13B | |
| +0.39% | 12.18B |
- Stock Market
- Equities
- STTK Stock